Scientific Advisors
  • Edison Liu, M.D.
    • Edison Liu is the President and CEO of the Jackson Laboratory, bringing his passion for personalized medicine to leading the development and utilization of complex mouse models for basic and translational research. Previously, he was the founding Executive Director of the Genome Institute of Singapore and served in similar capacities at the Singapore Cancer Syndicate and Singapore Tissue Network. Dr. Liu has won numerous awards for his work, most recently earning honors as Associate Member of the European Molecular Biology Organization (EMBO), Public Service Medal for 
    • controlling SARS in Singapore and an election to the board of directors at the American Association for Cancer Research. He is the President of the Human Genome Organisation (HUGO) and previously Chairman of the Health Sciences Authority in Singapore, among numerous other committees and advisory boards. Dr. Liu has authored more than 200 publications detailing his work on the involvement of kinases in cancer biology and molecular clinical epidemiology and functional genomics of human cancers. Dr. Liu earned his M.D. from Stanford University and was a resident at Barnes Hospital at Washington University, St. Louis.
  • Terry Speed, Ph.D.
    • Terry Speed is currently the head of the Bioinformatics Division of the Walter & Eliza Hall Institute of Medical Research in Melbourne, Australia. Previously, Terry was on the statistics faculty at the University of California at Berkeley, with a research focus on statistical aspects of genetics and molecular biology. His team conducted basic research, collaborating with other biomedical scientists at schools such as Stanford University, the University of Michigan, Cornell University Medical School and various University of California campuses. He has an extensive relationship with the Life Sciences Division of the Lawrence Berkeley National Laboratory
    • and has been closely involved with the U.S. National Cancer Institute’s Integrative Cancer Biology Program. Terry is a member of the Australian Cancer Research Foundation Centre for Therapeutic Target Discovery, the first initiative of the Melbourne Comprehensive Cancer Centre. He has a B.Sc. (Hons.) degree from the University of Melbourne and a Ph.D. from Monash University. His research is focused on applying statistics to biomedical research, concentrating on cancer genomics.

Clinical Advisors
  • Paul W. Ladenson, M.D.
    • Paul W. Ladenson is the John Eager Howard Professor of Endocrinology and Metabolism and Director of the Division of Endocrinology and Metabolism at the Johns Hopkins Medical Institutions. Dr. Ladenson was educated at Dartmouth College, Oxford University, and Harvard Medical School before training in Internal Medicine and in Endocrinology and Metabolism at the Massachusetts General Hospital. Dr. Ladenson has served as editor-in-chief of the Journal of Clinical Endocrinology and Metabolism and 
    • president of the American Thyroid Association. His research interests focus on thyroid cancer, thyroid hormone analogues, and health economic aspects of thyroid disease management.  He is a Distinguished University Professor at Johns Hopkins and a past recipient of the American Thyroid Association's Paul Starr Award for career achievements in thyroid research.
  • Steven I. Sherman, M.D., FACE
    • Steven I. Sherman is chair and professor at the Department of Endocrine Neoplasia and Hormonal Disorders at the University of Texas M.D. Anderson Cancer Center in Houston, Texas. Dr. Sherman also serves on the Medical Advisory Council of ThyCa: Thyroid Cancer Survivors’ Association and the thyroid cancer guidelines panels of both the National Comprehensive Cancer Network Guidelines Program and the American Thyroid Association. He
    • currently is Treasurer of the International Thyroid Oncology Group. His research interests include novel therapies and approaches toward treatment in thyroid carcinoma. Dr. Sherman has published more than 90 articles and editorials in peer-reviewed journals. He graduated from Johns Hopkins School of Medicine and is board-certified in internal medicine and endocrinology, diabetes and metabolism.
  • R. Michael Tuttle, M.D.
    • R. Michael Tuttle is currently an endocrinologist at the Memorial Sloan-Kettering Cancer Center in New York, New York and Professor at the Cornell School of Medicine. He is a board of directors member of the American Thyroid Association and serves on the Medical Advisory Council of ThyCa: Thyroid Cancer Survivors’ Association.
    • Dr. Tuttle’s research is focused on investigational therapies for thyroid cancer. He was educated at the University of Louisville School of Medicine and was a resident at the Dwight David Eisenhower Army Medical Center.